Revolution Medicines Statistics
Share Statistics
Revolution Medicines has 186.27M
shares outstanding. The number of shares has increased by 12.68%
in one year.
| Shares Outstanding | 186.27M |
| Shares Change (YoY) | 12.68% |
| Shares Change (QoQ) | 1.95% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,105 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 16.55M, so 8.9% of the outstanding
shares have been sold short.
| Short Interest | 16.55M |
| Short % of Shares Out | 8.9% |
| Short % of Float | 9.42% |
| Short Ratio (days to cover) | 9.11 |
Valuation Ratios
The PE ratio is -12.23 and the forward
PE ratio is -7.83.
Revolution Medicines's PEG ratio is
1.69.
| PE Ratio | -12.23 |
| Forward PE | -7.83 |
| PS Ratio | 0 |
| Forward PS | 4.6 |
| PB Ratio | 3.24 |
| P/FCF Ratio | -12.92 |
| PEG Ratio | 1.69 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Revolution Medicines.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.2,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 14.2 |
| Quick Ratio | 14.2 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.23 |
| Debt / FCF | -0.24 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-974,176.95 |
| Employee Count | 616 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 753K |
| Effective Tax Rate | 0.13% |
Stock Price Statistics
The stock price has increased by -2.43% in the
last 52 weeks. The beta is 1.11, so Revolution Medicines's
price volatility has been higher than the market average.
| Beta | 1.11 |
| 52-Week Price Change | -2.43% |
| 50-Day Moving Average | 37.77 |
| 200-Day Moving Average | 43.69 |
| Relative Strength Index (RSI) | 42.86 |
| Average Volume (20 Days) | 1,792,778 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -689.52M |
| Net Income | -600.09M |
| EBITDA | -589.02M |
| EBIT | -600.85M |
| Earnings Per Share (EPS) | -3.58 |
Full Income StatementBalance Sheet
The company has 543.06M in cash and 135.84M in
debt, giving a net cash position of 407.22M.
| Cash & Cash Equivalents | 543.06M |
| Total Debt | 135.84M |
| Net Cash | 407.22M |
| Retained Earnings | -1.74B |
| Total Assets | 2.37B |
| Working Capital | 1.98B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -557.44M
and capital expenditures -10.31M, giving a free cash flow of -567.74M.
| Operating Cash Flow | -557.44M |
| Capital Expenditures | -10.31M |
| Free Cash Flow | -567.74M |
| FCF Per Share | -3.38 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
